KYNB · Kyntra Bio Inc
United States · RS rating 11 · As of 2026-11-03
| Price | 4.31 USD |
|---|---|
| 1-day change | -3.4% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 13 / 14 / 16 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 3 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -107.1% |
| Sales growth Q/Q | +18.7% |
| Distance from 52-week high | +60.9% |
| Market cap (USD) | $28.4M |